trial similarly intends knock gene pd-1 knock second gene insert cells introduced patient year fda difficult predict given patient extent antibodies block pd-1 activate immune response contrast knocking gene blocks pd-1 greater certainty multiplying cells increases chance response powerful antibodies says timothy chan clinical research immunotherapy memorial sloan kettering cancer center new york city known genome potentially harmful effects chengdu medgencell biotechnology company collaborator trial validate cells ensure correct genes knocked cells introduced patients says oncologist lei deng west china hospital member lu team technique targets t cells involved kinds immune responses non specific way chan worries approach induce excessive